. Later, a retrospective analysis of the data collected was carried out to look at the effect of inappropriate initial antimicrobial therapy on the prognosis of patients with sepsis.
Inclusion criteria: All subjects enrolled met clinical criteria of severe sepsis defined as: objective signs of sepsis, >3 signs of SIRS, and at least two signs of hypoperfusion or organ dysfunction (hypoxaemia, acidosis, thromboctyopaenia, unexplained coagulopathy or oliguria), within the 12 hours before treatment.
Exclusion criteria: Hypotensive patients requiring vasopressors for > 4hrs were excluded as were those with predicted life expectancy < 3 months, those with DNAR orders, HIV, cardiogenic shock, organ transplantation, neutropenia secondary to chemotherapy, corticosteroid use (>0.5mg/kg/day), end-stage renal failure requiring dialysis, pancreatitis and liver disease.
Study Population: 1342 patients were randomised at 108 centres in North America and Europe. Mean age was 60.5 yrs (range 17-96). 61% were male, and 65% were admitted for medical management, 27% emergency surgery and 8% elective surgery. Both groups were well matched both demographically, and with respect to SAPS (II) and clinical parameters. Retrospective analysis for appropriate antibiotic therapy was only carried out on the 904 (67%) who met the criteria for microbiologically documented sepsis or early septic shock. The remainder were excluded from retrospective analysis. Mean age was 60 years +/-17 years and again 61% were male.
Intervention: Eligible patients received either a single i.v. injection of lenercept at 0.125mg/kg or placebo, over 5-7 minutes according to randomisation. All patients received standard supportive care and empirical antimicrobial treatment adapted to in-vitro susceptibility testing where appropriate.
Study procedures:
Personal data, vital signs, laboratory parameters, ECG, CXR reports and microbiological procedures were recorded 12 hours before drug administration and post-administration as necessary. Additionally, postadministration SAPS (II), GCS scores, respiratory and haemodynamic parameters were recorded. Adverse events were recorded at 1, 2, 3, 7, 14 and 28 days. Blood cultures were taken at baseline and on day 3. Specimens from other sites were taken as necessary. An established infection was considered to be present if a clinically relevant organism had been isolated within 3 days before study drug administration.
Retrospective Analysis: Microorganisms classified as causative of severe sepsis were used to assess appropriateness of empirical antimicrobial treatment. Appropriate therapy was classified as the use of at least one agent to which all causative microorganisms were sensitive within 24 hours from study drug infusion. Any identified resistance to, lack of, or delay in initiation of appropriate therapy (>24 hrs) for documented causative organisms, or the use of aminoglycoside therapy for non-fermenting gram negative bacilli, were classed as inappropriate. A propensity score was devised that adjusted for factors associated with inappropriate antimicrobial treatment. To calculate the propensity score for each individual patient a collection of predictors were collapsed into a single summarising predictor (a covariate) that represented the probability of that patient being treated inadequately.
Outcomes:
In both the original Lenercept article and the retrospective article under review 28-day all cause mortality was used as the primary endpoint.
Results: Lenercept had no significant effect on mortality in the original study 2 . 468 of the 904 patients in the second study were found to have positive blood cultures. The leading primary sites of infection were respiratory (40%; n=365), urinary (18%; n=165) and intra-abdominal (14%; n=123). The most frequently identified pathogens were E.Coli (25%), S.Aureus (18%), Str.pneumoniae (14%), pyogenes-like Streptococcus (14%), Enterococcus (10%), Klebsiella (10%) and P.aeuruginosa (9%). Polymicrobial infections were identified in 349 patients (39%). The most frequently associated multi-resistant organisms were P.aeuruginosa, S.maltophilia, Acinetobacter spp., MRSA (38%), Enterococci (26%) and fungal (20%) species.
Overall, 23% received inappropriate initial therapy, predominantly because one or more pathogens exhibited resistance (18%), but delay in treatment also rendered 5% of treatments inappropriate. There was no statistically significant difference in inappropriate therapy between the lenercept and placebo arms (P=0.18); however, inappropriate therapy was statistically more likely if the patient was male (p<0.02), treated in Europe, on a surgical ward, had a community acquired or late (>7days) nosocomial, fungal or polymicrobial infection (all P<0.001).
The overall mortality was 28% in the adequately treated group vs. 39% in the inappropriate group (p<0.001) and multivariate analysis, when adjusted for confounding factors (demographic comorbidity, SAPS (II), baseline organ dysfunction, characteristics of infection and propensity score) showed that inappropriate initial antimicrobial therapy was independently associated with increased mortality (OR = 1.8, 95% CI: 1.2-2.6). This was unaffected by centre in which grouped patients were treated.
Discussion
This study shows a clear mortality benefit in those treated with appropriate initial antimicrobial chemoprophylaxis. In the recent past there have been conflicting reports regarding the frequency of inadequate antimicrobial therapy and it's effect on mortality in the critically ill 1, 3 . Although the evidence of a statistical association between inadequate therapy and mortality does not prove causality, the robust multivariate analysis in this paper suggests that the mortality is not explained by confounding factors alone. This is a large, multinational cohort of patients with a heterogeneous population similar to those seen in most general intensive care units in the UK and is therefore applicable to our usual practice.
Limitations of the study, which are acknowledged by the authors, include the narrow definition of adequacy of treatment, the reliance of local investigators to determine causative agents and the fact that the wider implication of broad-spectrum therapy was not assessed. Assessing any difference in the overall quality of patient care between centres was also not addressed and could potentially influence mortality.
On the data presented there is a clear warning that we need to remain vigilant in our search for causative microorganisms and be meticulous in our selection of appropriate agents. As commented on in the paper's accompanying editorial these agents must also be tailored down according to the remaining organisms sensitivities and treatment should be timely, continued no longer than absolutely necessary and used with thought given to optimal dosing intervals, drug interactions and appropriate serum concentrations 4 .
Finally, it is also necessary to use local medical intelligence on the usual pathogens and their sensitivities seen within individual hospitals, and any so called 'antibiograms' should be audited regularly to address the changing temporal patterns of nosocomial infection sensitivity. Only then will this will allow delivery of initial appropriate antibiotic therapy.
